Comparison between decitabine and azacitidine for patients with acute myeloid leukemia and higher-risk myelodysplastic syndrome: a systematic review and network …
J Ma, Z Ge - Frontiers in pharmacology, 2021 - frontiersin.org
Background: The hypomethylating agents (HMAs) azacitidine (AZA) and decitabine (DAC)
have been widely used in patients with acute myeloid leukemia (AML) and higher-risk …
have been widely used in patients with acute myeloid leukemia (AML) and higher-risk …
Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines
Anaemia and iron deficiency (ID) are frequent complications in patients with solid tumours or
haematological malignancies, particularly in patients treated with chemotherapeutic agents …
haematological malignancies, particularly in patients treated with chemotherapeutic agents …
Azacitidine in adult patients with acute myeloid leukemia
AC Schuh, H Döhner, L Pleyer, JF Seymour… - Critical reviews in …, 2017 - Elsevier
Azacitidine is recommended front-line treatment for older patients with acute myeloid
leukemia (AML) who are not candidates for intensive treatment regimens, and was recently …
leukemia (AML) who are not candidates for intensive treatment regimens, and was recently …
A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS
P Fenaux, V Santini, MAA Spiriti, A Giagounidis… - Leukemia, 2018 - nature.com
Erythropoiesis-stimulating agents are first choice for treating anemia in low-risk MDS. This
double-blind, placebo-controlled study assessed the efficacy and safety of epoetin-α in IPSS …
double-blind, placebo-controlled study assessed the efficacy and safety of epoetin-α in IPSS …
[HTML][HTML] Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes
N Gattermann, C Finelli, M Della Porta, P Fenaux… - …, 2012 - ncbi.nlm.nih.gov
Background Reductions in transfusion requirements/improvements in hematologic
parameters have been associated with iron chelation therapy in transfusion-dependent …
parameters have been associated with iron chelation therapy in transfusion-dependent …
[HTML][HTML] A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within …
SD Gore, P Fenaux, V Santini, JM Bennett… - …, 2013 - ncbi.nlm.nih.gov
The phase III AZA-001 study established that azacitidine significantly improves overall
survival compared with conventional care regimens (hazard ratio 0.58 [95% confidence …
survival compared with conventional care regimens (hazard ratio 0.58 [95% confidence …
Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient‐related factors and measuring from time of first red blood cell …
HA Leitch, A Parmar, RA Wells… - British Journal of …, 2017 - Wiley Online Library
Analyses suggest iron overload in red blood cell (RBC) transfusion‐dependent (TD) patients
with myleodysplastic syndrome (MDS) portends inferior overall survival (OS) that is …
with myleodysplastic syndrome (MDS) portends inferior overall survival (OS) that is …
Deferasirox for transfusion‐dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS 0306 T rial)
E Angelucci, V Santini, AA Di Tucci… - European journal of …, 2014 - Wiley Online Library
Background In the absence of randomized, controlled trial data to support iron chelation
therapy in transfusion‐dependent patients with myelodysplastic syndromes (MDS) …
therapy in transfusion‐dependent patients with myelodysplastic syndromes (MDS) …
[HTML][HTML] Trends in incidence, initial treatment and survival of myelodysplastic syndromes: a population-based study of 5144 patients diagnosed in the Netherlands …
AG Dinmohamed, O Visser, Y van Norden… - European Journal of …, 2014 - Elsevier
Background Studies with long-term follow-up of patients with myelodysplastic syndromes
(MDS) based on data from nationwide population-based cancer registries are lacking. We …
(MDS) based on data from nationwide population-based cancer registries are lacking. We …
MRI-based liver iron content predicts for nonrelapse mortality in MDS and AML patients undergoing allogeneic stem cell transplantation
M Wermke, A Schmidt, JM Middeke, K Sockel… - Clinical Cancer …, 2012 - AACR
Purpose: Retrospective, surrogate marker–based studies have found inconsistent
associations between systemic iron overload (SIO) and adverse outcome in patients …
associations between systemic iron overload (SIO) and adverse outcome in patients …